Associate Professor Frank Naya in Biology has been awarded a one-year research grant by Pfizer Inc. to investigate the efficacy of a bispecific antibody (developed by Pfizer) in ameliorating the accelerated muscle degeneration, inflammation, and fibrosis that occur in one form of congenital muscular dystrophy (CMD). This collaborative research project will focus on testing the above therapeutic approach on an engineered mouse model that displays the severity and disease progression of MDC1A, a human CMD caused by a mutation in laminin, an extracellular matrix protein required for muscle fiber attachment and integrity. Congratulations to Professor Naya on this award!